PKD2 mediates multi-drug resistance in breast cancer cells through modulation of P-glycoprotein expression

Cancer Letters

Volumn 300, Issue 1, 2011, Pages 48-56

  Chen, Jiao ^a   Lu, Libing ^a   feng, Yun ^a   Wang, Hui ^a   Dai, Lila ^a   li, Yan ^a   Zhang, Ping ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Multi drug resistance (MDR); P glycoprotein (P gp); Paclitaxel; PKD2

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GLYCOPROTEIN P; PACLITAXEL; PROTEIN KINASE D;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; P-GLYCOPROTEIN; PACLITAXEL; PHOSPHORYLATION; TRPP CATION CHANNELS;

EID: 78549242936     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.09.005     Document Type: Article

References (33)

1. Cui D., Xu Q., Wang K., Che X. Gli1 is a potential target for alleviating multidrug resistance of gliomas. J. Neurol. Sci. 2010, 288(1-2):156-166.
2. Simon S.M., Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc. Natl. Acad. Sci. USA 1994, 91(9):3497-3504.
3. Endicott J.A., Ling V. The biochemistry of p-glycoprotein- mediated multidrug resistance. Annu. Rev. Biochem. 1989, 58:137-171.
4. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2(1):48-58.
5. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan L., Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 1999, 39:361-398.
6. Nobili S., Landini I., Giglioni B., Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr. Drug. Targets 2006, 7(7):861-879.
7. Hait W.N., Yanf J.M. Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it. Semin. Oncol. 2005, 32(6 Suppl 7):S16-S21.
8. Choi J.H., Lim H.Y., Joo Hj, Kim H.S., Yi J.W., Kim H.C., Cho Y.K., Kim M.W., Lee K.B. Expression of multidrug resistance-associated protein I, p-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-Fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Brit. J. Cancer 2002, 86(10):1578-1585.
9. Oue T., Yoneda A., Uehara S., Yamanaka H., Fukuzawa M. Increased expression of multidrug resistance-associated genes after chemotherapy in pediatric solid malignancies. J. Pediatr. Surg. 2009, 44(2):377-380.
10. Hofmann J. Protein kinase C isozymes as potential targets for anticancer therapy. Curr. Cancer Drug. Targets 2004, 4(2):125-146.
11. Spitaler M., Utz I., Hilbe W., Hofmann J., Grunicke H.H. PKC-independent modulation of multidrug resistance in cells with mutant (V185) but not wild-type (G185) P-glycoprotein by bryostatin 1. Biochem. Pharmacol. 1998, 56(7):861-869.
12. Chaudhary P.M., Roninson I.B. Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists. Oncol. Res. 1992, 4(7):281-290.
13. Xianling Guo, Nannan Ma, Jin Wang, Jianrui Song, Xinxin Bu Increased p-38-MAKP is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer 2008, 8:375-384.
14. Bagowski C.P., Stein-Gerlach M., Choidas A., Ullrich A. Cell-type specific phosphorylation of threonines T654 and T669 by PKD defines the signal capacity of the EFG receptor. EMBO J. 1999, 18:5567-5576.
15. Hurd C., Rozengurt E. Protein kinase D is sufficient to suppress EGF-induced c-Jun Ser 63 phosporylation. Biochem. Biophys. Res. Commun. 2001, 282:404-408.
16. Paolucci L., Rozengurt E. Protein kinase D in small cell lung cancer cells: rapid activation through protein kinase C. Cancer Res. 1999, 59(3):572-577.
17. Guan J., Chen X.P., Zhu H., Luo S.F., Cao B., Ding L. Involvement of extracellular signal-regulated kinase/mitogen-activated protein kinase pathway in multidrug resistance induced by HBx in hepatoma cell line. World J. Gastroenterol. 2004, 10(23):3522-3527.
18. Van Lint J., Rykx A., Maeda Y., Vantus T., Sturany S., Malhotra V., Vandenheede J.R., Seufferlein T. Protein kinase D: an intracellular traffic regulator on the move. Trends Cell Biol. 2002, 12(4):193-200.
19. Sturany S., Van Lint J., Muller F., Wilda M., Hameister H., Hocker M., Brey A., Gern U., Vandenheede J., Gress T., Adler G., Seufferlein T. Molecular cloning and characterization of the human protein kinase D2, A novel member of the protein kinase D family of serine threonine kinases. J. Biol. Chem. 2001, 276(5):3316-3318.
20. Rey O., Yuan J., Young S.H., Rozengurt E. Protein kinase C nu/protein kinase D3 nuclear localization, catalytic activation, and intracellular redistribution in response to G protein-coupled receptor agonists. J. Biol. Chem. 2003, 278(26):23773-23785.
21. Enrique R., Osvaldo R., Richard T.W. Protein kinase D signaling. J. Biol. Chem. 2005, 280(14):13205-13208.
22. Terence T.C., Wai Yin L., Mary P.M., Robert M.S., Enrique R. Protein kinase D2 mediates lysophophatidic acid-induced interleukin8 production in nontransformed human colonic epithelial cells through NF-κB. Am. J. Physiol. Cell Physiol. 2007, 292:767-777.
23. Sinnett-Smith J., Jacamo R., Kui R., Wang Y.M., Young S.H., Rey O., Waldron R.T., Rozengurt E. Protein kinase D mediates mitogenic signaling by Gq-coupled receptors through protein kinase C-independent regulation of activation loop Ser744 and Ser748 phosphorylation. J. Biol. Chem. 2009, 284(20):13434-13445.
24. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
25. Guha S., Rey O., Rozengurt E. Neurotensin induces protein kinase C-dependent protein kinase D activation and DNA synthesis in human pancreatic carcinoma cell line PANC-1. Cancer Res. 2002, 62(6):1632-1640.
26. Mihailovic T., Marx M., Auer A., Van Lint J., Schmid M., Weber C., Seufferlein T. Protein kinase D2 mediates activation of nuclear factor kappaB by Bcr-Abl in Bcr-Abl+ human myeloid leukemia cells. Cancer Res. 2004, 64(24):8939-8944.
27. John J.R. Expression strategies for short hairpin RNA interference triggers. Hum. Gene Ther. 2008, 19(4):313-317.
28. Rao D.D., Vorhies J.S., Senzer N., Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv. Drug Deliv. Rev. 2009, 61(9):746-759.
29. Rey O., Young S.H., Cantrell D., Rozengurt E. Rapid protein kinase D translocation in response to G protein-coupled receptor activation. Dependence on protein kinase C. J. Biol. Chem. 2001, 276(35):32616-32626.
30. Liljedahl M., Maeda Y., Colanzi A., Ayala I., Van Lint J., Malhotra V. Protein kinase D regulates the fission of cell surface destined transport carriers from the trans-Golgi network. Cell 2001, 104(3):409-420.
31. Wani M.C., Taylor H.L., Wall M.E., Coggon P., McPhail A.T. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 1971, 93:2325-2327.
32. Rowinsky E.K., Donehower R.C. Paclitaxel (Taxol). New Engl. J. Med. 1995, 332:1004-1014.
33. Rowinsky E.K., Cazenave L.A., Donehower R.C. Taxol: a novel investigational antimicrotubule agent. J. Natl. Cancer Inst. 1990, 82:1247-1259.